We characterized a regulatory mechanism of circRNA-mediated immune evasion in NSCLC and highlighted that circIGF2BP3 may act as a potential therapeutic target to increase the efficacy of PD-1 antibodies. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.